How to Strengthen Heart Valves Naturally
This Clinical Trial Wants To Test Less Toxic Treatments For Blood Cancers
The National Institutes of Health (NIH) has launched a new clinical trial to revolutionize the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The myeloMATCH trial is all about finding the perfect treatment for each patient's unique cancer.
In this trial, doctors will analyze each patient's cancer cells to identify their specific genetic mutations. Then, they'll match the patient to a treatment that targets those mutations. This personalized approach could lead to more effective and less toxic treatments like chemo.
Black Americans face a disproportionate burden of blood cancers, including multiple myeloma, a disease that affects the bone marrow and leads to the overproduction of abnormal plasma cells. This disparity is attributed to a complex interplay of factors, such as socioeconomic inequalities, limited access to healthcare, and historical biases in medical research.
One of the biggest challenges in blood cancer research is the lack of diversity in clinical trials. Black Americans, in particular, are often underrepresented. The myeloMATCH trial is committed to changing that by making the trial available to patients in communities across the country.
By including a diverse group of patients, researchers can learn more about how different genetic mutations affect treatment outcomes in different populations. This will help them develop treatments that work better for everyone.
The myeloMATCH trial is part of a larger effort by the NIH to find more personalized cancer treatments. By conducting these trials, they're bringing cutting-edge science to patients where they live and ensuring that everyone can benefit from the latest research.
Overall, the myeloMATCH trial offers hope for a new era of blood cancer treatment. By targeting the specific genetic mutations in each patient's cancer, doctors may be able to develop more effective and personalized therapies.
Click here to learn more about how to join this study.
Hemogenyx Pharmaceuticals PLC Announces Schedule For Phase I Clinical Trial Opening
Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1)
LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases, is pleased to announce the schedule for the opening of the first clinical site for its lead asset, HEMO-CAR-T, formally designated HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults.
The Company has successfully completed the necessary contracts and budgeting preparations to advance HG-CT-1 into clinical testing. Institutional Review Board (IRB) approval at the initial clinical site is anticipated by the second week of November. Following IRB clearance, a Site Initiation Visit (SIV) is expected to take place in the third week of November, marking the official launch of the Phase I clinical trial.
This Phase I trial is designed as a dose-escalation study to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:
Efficacy of HG-CT-1 based on AML-specific response criteria
Overall survival (OS) rates among participating subjects
Progression-free survival (PFS) in evaluable subjects
Duration of response (DoR) in those who achieve clinical responses
These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. The commencement of this trial will represent a major milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"Launching this Phase I clinical trial for HG-CT-1 will mark a critical step forward in our mission to develop transformative therapies for patients battling relapsed and refractory acute myeloid leukemia. For patients who have few remaining treatment options, HG-CT-1 offers a potentially life-saving solution. We are eager to initiate this trial and generate data that will be essential in advancing this therapy toward broader clinical use. This milestone underscores our commitment to innovation and our dedication to addressing the urgent needs of patients with severe blood cancers."
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective forms of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease.
Story Continues
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
Enquiries:
Hemogenyx Pharmaceuticals plc
https://hemogenyx.Com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
headquarters@hemogenyx.Com
Peter Redmond, Director
peter.Redmond@hemogenyx.Com
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited
Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
About Hemogenyx Pharmaceuticals plcHemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.Com or visit www.Rns.Com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.Com
The Realities Of Living With Leukemia
A leukemia diagnosis can feel like a sudden storm, upending lives and leaving patients and families grappling with uncertainty. This blood cancer, which affects the body's ability to produce healthy blood cells, presents unique challenges that extend far beyond the physical symptoms. As medical advancements continue to improve outcomes, understanding the full impact of leukemia becomes crucial for patients, caregivers, and society at large.
The cellular rebellionAt its core, leukemia is a revolt within the body's blood-forming tissues. The bone marrow, typically a factory for healthy blood cells, begins producing abnormal white blood cells at an alarming rate. These rogue cells, unable to perform their intended function, crowd out healthy cells and wreak havoc on the body's defenses.
Hematologists categorize leukemia into four main types:
Each type presents its own set of challenges, with acute forms progressing rapidly and chronic forms developing over time. The distinction is crucial, as it often dictates the urgency and nature of treatment.
The body under siegeThe effects of leukemia extend far beyond the bone marrow. As abnormal cells proliferate, patients often experience a constellation of symptoms that can be both bewildering and debilitating.
Fatigue, often profound and unrelenting, is a hallmark of the disease. The body, deprived of healthy red blood cells, struggles to deliver oxygen efficiently, leaving patients feeling drained even after minimal exertion.
Increased susceptibility to infections is another common concern. With the immune system compromised, even minor illnesses can pose significant risks. Patients find themselves navigating a world where everyday interactions suddenly carry the weight of potential health hazards.
Unexplained bruising and bleeding complete the triad of classic leukemia symptoms. The shortage of platelets, crucial for blood clotting, leaves patients vulnerable to prolonged bleeding from even minor injuries.
The emotional tsunamiWhile the physical toll of leukemia is evident, the emotional impact can be equally profound. Patients often describe the initial diagnosis as a surreal experience, akin to standing at the edge of a precipice.
Fear, anger, and confusion swirl together, creating an emotional maelstrom that can be overwhelming. The uncertainty of the future, coupled with the immediate need for life-altering decisions, can leave patients feeling adrift.
Psychologists specializing in oncology stress the importance of addressing these emotional challenges head-on. Many cancer centers now offer integrated care that includes mental health support, recognizing that emotional well-being plays a crucial role in overall treatment outcomes.
The treatment battlefieldModern leukemia treatment is a testament to medical advancement, offering hope where once there was little. However, the road to remission is often long and fraught with challenges.
Chemotherapy remains the cornerstone of most leukemia treatment plans. This powerful tool in the fight against cancer comes with its own set of side effects, from hair loss to nausea, that patients must navigate.
For some, targeted therapies offer a more precise approach, homing in on specific cellular abnormalities with fewer systemic side effects. These treatments, while promising, are not without their own challenges and are not suitable for all types of leukemia.
Stem cell transplants represent the frontier of leukemia treatment, offering the potential for a cure in some cases. However, the procedure is intense, requiring careful donor matching and a period of severe immune suppression that carries its own risks.
Life in the new normalFor many leukemia patients, life becomes divided into "before" and "after" diagnosis. Adapting to this new normal requires resilience and often a complete reevaluation of priorities.
Nutrition takes on new importance, with many patients working closely with dietitians to ensure their bodies have the fuel needed to fight the disease and withstand treatment. Exercise, once perhaps taken for granted, becomes a carefully monitored activity, balancing the need for physical activity with the realities of a compromised immune system.
Work and social lives often require adjustment. Many patients find themselves navigating the complexities of medical leave and disability benefits while also managing the expectations of friends and family who may not fully understand the invisible nature of their struggle.
The ripple effectThe impact of leukemia extends far beyond the individual patient. Families and caregivers often find themselves thrust into roles they never anticipated, balancing emotional support with practical care.
Support groups have emerged as a vital resource, providing a space for patients and caregivers to share experiences and coping strategies. Many find solace in connecting with others who truly understand the day-to-day realities of living with leukemia.
The broader societal impact of leukemia is also significant. Advances in treatment have turned what was once often a fatal diagnosis into a chronic condition for many, raising new questions about long-term care and quality of life.
Glimpses of hopeDespite the challenges, many leukemia patients find unexpected sources of strength and resilience. Stories of personal growth, renewed appreciation for life, and deep connections forged through shared struggle are common.
Medical researchers continue to push the boundaries of treatment, with immunotherapies and gene-editing technologies offering new avenues of hope. Clinical trials provide access to cutting-edge treatments, although they come with their own set of uncertainties.
For those facing a leukemia diagnosis, the road ahead may be daunting, but it is not without hope. With advances in treatment, strong support systems, and a growing understanding of the holistic needs of cancer patients, many are finding ways to not just survive, but thrive in the face of this challenging disease.
In the end, the story of leukemia is not just one of medical triumph over disease, but of human resilience in the face of profound adversity. It's a reminder of the strength of the human spirit and the power of community in facing life's greatest challenges.
This story was created using AI technology.
Comments
Post a Comment